Brendon Stiles on Twitter: "RT @StephenVLiu: Dr. Tina Cascone with a thoughtful #ASCOPlenarySeries discussion on NEOTORCH & the rapidly evolving paradigms for perioper…" / Twitter
MD Anderson Cancer Center on Twitter: "Dr. Tina Cascone shares novel neoadjuvant immunotherapy combination strategies at #ASCO22. #EndCancer https://t.co/e4HZNszqVN" / Twitter
Harnessing Tertiary Lymphoid Structures for Improved Immunotherapeutic Strategies in Cancer Patients | The Mark Foundation for Cancer Research
Tina Cascone on NSCLC New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy - The ASCO Post
Annual Meeting 2022: The New Frontier of Immunotherapy in Lung Cancer—Boosting the Immune Response Before Surgery - American Association for Cancer Research (AACR)
Michael Kroll, MD (@BenignHemeMHK) / Twitter
Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do
Dr. Cascone on Remaining Challenges With Perioperative Immunotherapy in NSCLC - YouTube
8 perfiles de «Martina Cascone» | LinkedIn
Tina Cascone | MD Anderson Cancer Center
Driven by Passion, Directed by Data
Dr. Tina Cascone, MD – Houston, TX | Hematology
Tina Cascone on NSCLC New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy - The ASCO Post
Thoughts About K4D: The Future is Now, and Watson is its Name
Nikki Cascone at Shut Up & Eat Party celebrating 2 Years of 24 Prince New York City, USA - 08.04.08 Tina Paul Stock Photo - Alamy
Dr. Tina Cascone - doctoryouneed.org Doctor You Need
Tina Cascone | MD Anderson Cancer Center
Our Young Investigators - GO2 for Lung Cancer
Virtual Tumor Board: Resectable Stage III NSCLC | IASLC
Harnessing Tertiary Lymphoid Structures for Improved Immunotherapeutic Strategies in Cancer Patients | The Mark Foundation for Cancer Research
ESMO - Eur. Oncology on Twitter: "#ESMO18: Tina Cascone reports on key results from LBA49: Neoadjuvant nivolumab or nivolumab plus ipilimumab for resectable non-small-cell lung cancer #NSCLC #LCSM https://t.co/cFK46GQA23 https://t.co/p4PAZfkdrI" / Twitter
IDEOlogy Health on Twitter: "What an honor to have the incredible Dr. Tina Cascone as Co-Chair for the @TLCconference! Join us this March to learn the latest on #Immunotherapy in NSCLC from
donington on Twitter: "So much fun presenting at #TexasLung23!!!! The bar has been set high for other meetings: great faculty & excellent talks in a tremendous venue. @TLCconference is the new not-to-miss
TINA CASCONE, M.D., PH.D., Medical Oncology HOUSTON, TX - Profile
Neoadjuvant Nivolumab/Ipilimumab Shows Promise in Resectable NSCLC
Dr. Tina Cascone - doctoryouneed.org Doctor You Need
What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non–Small-Cell Lung Cancer | Journal of Clinical Oncology
